Low methylation levels of the SFRP1 gene are associated with the basal-like subtype of breast cancer

Jeong,Young  Ju; Jeong,Hye  Yeon; Bong,Jin  Gu; Park,Sung  Hwan; Oh,Hoon  Kyu

doi:10.3892/or.2013.2335

Low methylation levels of the SFRP1 gene are associated with the basal-like subtype of breast cancer

Authors:
- Young Ju Jeong
- Hye Yeon Jeong
- Jin Gu Bong
- Sung Hwan Park
- Hoon Kyu Oh
View Affiliations

Affiliations: Department of Surgery, College of Medicine, Catholic University of Daegu, Daegu 705-718, Republic of Korea, Department of Pathology, College of Medicine, Catholic University of Daegu, Daegu 705-718, Republic of Korea
Published online on: March 6, 2013 https://doi.org/10.3892/or.2013.2335
Pages: 1946-1954

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epigenetic analyses have shown that aberrant DNA methylation signatures are associated with breast cancer molecular subtypes. In this study, we analyzed the methylation status of breast cancer-related genes in relation to the molecular subtypes and investigated whether the basal-like subtype displays distinct methylation profiles. By using pyrosequencing, we analyzed the DNA methylation status of 5 candidate genes in 60 breast cancer samples. We compared the methylation frequency across the molecular subtypes and analyzed the correlation between methylation levels and clinicopathological characteristics. A total of 59 cases displayed aberrant methylation. Amplification during polymerase chain reaction analysis failed in 1 case. The median methylation levels of the secreted frizzled-related protein 1 (SFRP1) gene were significantly lower in the basal-like subtype compared to the luminal A, luminal B and human epidermal growth factor receptor 2 (HER2) subtypes. Cadherin 13 (H-cadherin; CDH13) methylation levels were significantly higher in the HER2 tumors compared to the luminal A and basal-like subtypes. A comparison of the methylation status with clinicopathological characteristics revealed that the expression of bcl-2, progesterone receptor and epidermal growth factor receptor were associated with SFRP1 gene methylation status. Our results indicate that the basal-like subtype is associated with low methylation levels of the SFRP1 gene, suggesting that the methylation levels of specific breast cancer genes may potentially serve as epigenetic biomarkers and prognostic factors.

View Figures

View References

1	Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
2	Sørlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003.PubMed/NCBI
3	Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 27:1160–1167. 2009. View Article : Google Scholar : PubMed/NCBI
4	Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
5	Cheang MCU, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar
6	Jaenisch R and Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 33:245–254. 2003. View Article : Google Scholar : PubMed/NCBI
7	Dworkin AM, Huang TH and Toland AE: Epigenetic alterations in breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 19:165–171. 2009. View Article : Google Scholar : PubMed/NCBI
8	Widschwendter M and Jones PA: DNA methylation and breast carcinogenesis. Oncogene. 21:5462–5482. 2002. View Article : Google Scholar : PubMed/NCBI
9	Bediaga N, Acha-Sagredo A, Guerra I, et al: DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. 12:R772010. View Article : Google Scholar : PubMed/NCBI
10	Holm K, Hegardt C, Staaf J, et al: Molecular sybtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 12:R362010. View Article : Google Scholar : PubMed/NCBI
11	Goldhirsch A, Wood WC, Coates AS, et al: Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
12	Huang DW, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
13	Wang S, Dorsey TH, Terunuma A, Kittles RA, Ambs S and Kwabi-Addo B: Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One. 7:e379272012.PubMed/NCBI
14	Rattner A, Hsieh JC, Smallwood PM, et al: A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sci USA. 94:2859–2863. 1997. View Article : Google Scholar : PubMed/NCBI
15	Finch PW, He X, Kelley MJ, et al: Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc Natl Acad Sci USA. 94:6770–6775. 1997. View Article : Google Scholar : PubMed/NCBI
16	Cadigan KM and Nusse R: Wnt signaling: a common theme in animal development. Genes Dev. 11:3286–3305. 1997. View Article : Google Scholar : PubMed/NCBI
17	Polakis P: Wnt signaling and cancer. Genes Dev. 14:1837–1851. 2000.
18	Ugolini F, Adélaïde J, Charafe-Jauffret E, et al: Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene. 18:1903–1910. 1999. View Article : Google Scholar
19	Klopocki E, Kristiansen G, Wild PJ, et al: Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol. 25:641–649. 2004.PubMed/NCBI
20	Liedtke C, Ruckert C, Goette M, et al: Secreted frizzled receptor protein 1 (sFRP-1) as both a potential novel biomarker of triple negative breast cancer (TNBC), and its sensitivity against taxane/anthracycline containing neoadjuvant chemotherapy. Cancer Res. 69(24 Suppl): 40472009. View Article : Google Scholar
21	Veeck J, Niederacher D, An H, Klopocki E, et al: Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene. 25:3479–3488. 2006. View Article : Google Scholar : PubMed/NCBI
22	Fiegl H, Millinger S, Goebel G, et al: Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res. 66:29–33. 2006. View Article : Google Scholar : PubMed/NCBI
23	Celebiler CA, Kilic Y, Saydam S, et al: Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer. Cancer Sci. 100:2341–2345. 2009. View Article : Google Scholar : PubMed/NCBI
24	Hinshelwood RA and Clark SJ: Breast cancer epigenetics: normal human mammary epithelial cells as a model system. J Mol Med. 86:1315–1328. 2008. View Article : Google Scholar : PubMed/NCBI
25	Lo PK and Sukumar S: Epigenomics and breast cancer. Pharmacogenomics. 9:1879–1902. 2008. View Article : Google Scholar : PubMed/NCBI
26	Feng W, Shen L, Wen S, et al: Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 9:R572007. View Article : Google Scholar : PubMed/NCBI
27	Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
28	Yuan Y, Mendez R, Sahin A and Dai JL: Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 61:5558–5561. 2001.PubMed/NCBI
29	Raish M, Dhillon VS, Ahmad A, et al: Promoter hypermethylation in tumor suppressing genes p16 and FHIT and their relationship with estrogen receptor and progesterone receptor status in breast cancer patients from Northern India. Transl Oncol. 2:264–270. 2009. View Article : Google Scholar
30	Du Y, Carling T, Fang W, Piao Z, Sheu JC and Huang S: Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res. 61:8094–8099. 2001.PubMed/NCBI